Chronic inflammation-responsive hydrogel restores myeloid-T cell crosstalk to reinvigorate antitumor immunity against metastatic colorectal cancer
Authors:
- Xinchao LiXLXinchao Li
- Wangxian FuWFWangxian Fu
- Hao LeHLHao Le
- Rui LuoRLRui Luo
- Yingjie LiYLYingjie Li
- Xiaorong KouXKXiaorong Kou
- Tao HeTHTao He
- Liping BaiLBLiping Bai
- Yangsong XuYXYangsong Xu
- Jiayi CaoJCJiayi Cao
- Yixi WangYWYixi Wang
- Xinmao YuXYXinmao Yu
Open Access
- 1 August 2026
- journal article
- Published by KEAI Publishing in Bioactive Materials
- Vol. 62, 263-281
Abstract
Chronic inflammation in intermediate/advanced tumors drives burdensome protumor immune cell communication, thereby weakening immunotherapy. Conventional anti-inflammatory therapies focus on alleviating chronic inflammation whereas ignore dysfunction and scarcity of myeloid and T cells, which hinder their intercellular communication restoration. To address the dilemma, an inflammatory condition-triggered protumor inflammation-immunosurveillance shift hydrogel (TRANS) is developed to initiate adaptive immune responses mediated by intercellular communication. Triggered by inflammatory conditions, TRANS releases celecoxib (CXB) to inhibit the COX-2/PGE2 pathway, thereby reprogramming tumor-associated macrophages and mitigating protumor inflammation. Furthermore, TRANS incorporates FMS-like tyrosine kinase 3 ligands (Flt-3L) and 4-1BB agonists (α-CD137) to respectively recruit type 1 conventional DC (cDC1) and revitalize tumor-infiltrating T cells, to rejuvenate immunosurveillance. TRANS inhibits 87.50% and 88.74% of primary and secondary colorectal tumors, generates antitumor immune memory to resist tumor rechallenge, and significantly reduces lung and liver metastases. Rechallenge model shows TRANS leads to antitumor immune memory formation. Single-cell RNA sequencing is preform to elucidate the mechanism of TRANS, which exhibits that TRANS exerts antitumor effects by optimizing the crosstalk between myeloid cells and T cells via CXCL9/10-CXCR3/DPP4. TRANS further gains better control of colorectal cancer when combined with immune checkpoints inhibitors. This study offers a novel perspective on immunotherapy by rebalancing inflammation-immunity dynamics.Keywords
Funding Information
- National Natural Science Foundation of China (82572418)
- National Natural Science Foundation of China (82372123)
- Key Research and Development Program of Ningxia (2023BEG02001)
- Key Technologies Research and Development Program
- West China Hospital, Sichuan University (ZYYC23004)
- Sichuan University
- National Key Research and Development Program of China (2023YFB3810000)
This publication has 67 references indexed in Scilit:
- Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunityCancer Cell, 2024
- A programmable releasing versatile hydrogel platform boosts systemic immune responses via sculpting tumor immunogenicity and reversing tolerogenic dendritic cellsBiomaterials, 2023
- In vivo macrophage engineering reshapes the tumor microenvironment leading to eradication of liver metastasesCancer Cell, 2023
- The evolving tumor microenvironment: From cancer initiation to metastatic outgrowthCancer Cell, 2023
- Immune phenotypic linkage between colorectal cancer and liver metastasisCancer Cell, 2022
- Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulationCancer Cell, 2021
- Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast CancerJAMA Oncology, 2021
- Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon CancerJAMA, 2021
- Understanding cell‐cell communication and signaling in the colorectal cancer microenvironmentClinical and Translational Medicine, 2021
- Multifaceted roles of PGE2 in inflammation and cancerSeminars in Immunopathology, 2012